Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
G8 CAR T cells
- Development stage
- Preclinical
- Lead developer
- National Institutes of Health
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
G8 CAR T cells are an experimental adoptive cell therapy consisting of T cells engineered to express a chimeric antigen receptor (CAR) derived from a novel B7-H3-specific nanobody (VHH). Developed by researchers at the National Institutes of Health (NIH), these CAR T cells target B7-H3 (CD276), a transmembrane protein overexpressed in various solid tumors and tumor-associated myeloid cells, while showing limited expression in normal tissues. The G8 clone was isolated from a camelid VHH phage display library and has demonstrated potent in vitro cytolytic activity against B7-H3-positive pancreatic ductal adenocarcinoma (PDAC) and neuroblastoma (NB) cell lines. While other clones like C4 and B12 showed superior in vivo efficacy in metastatic PDAC and NB mouse models in the same study, G8 remains a specific candidate within this nanobody-based CAR-T platform for treating solid tumors.
- Other names
- G8 B7-H3 CAR-TG-8 B7-H3 CAR-TG 8 B7-H3 CAR-TG8 nanobody-based CAR T cellsG-8 nanobody-based CAR T cellsG 8 nanobody-based CAR T cells
02
Targets
B7-H3
Beyond the preview
Go deeper on G8 CAR T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on G8 CAR T cells.